for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

66.86USD

Change

-0.04(-0.06%)

Volume

4,878,516

Today's Range

66.80

 - 

67.31

52 Week Range

56.56

 - 

73.34

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

U.S. Food And Drug Administration Approves Expanded Indication Of Gilead’S Biktarvy For Treatment Of HIV-1 In Pediatric Populations

Oct 18 (Reuters) - Gilead Sciences Inc <GILD.O>::U.S. FOOD AND DRUG ADMINISTRATION APPROVES EXPANDED INDICATION OF GILEAD’S BIKTARVY® FOR TREATMENT OF HIV-1 IN PEDIATRIC POPULATIONS.GILEAD SCIENCES INC - FDA APPROVES LOW-DOSE TABLET FOR HIV TREATMENT IN VIROLOGICALLY SUPPRESSED CHILDREN WEIGHING AT LEAST 14 KG.GILEAD SCIENCES INC - APPROVED A NEW LOW-DOSE TABLET DOSAGE FORM OF BIKTARVY FOR PEDIATRIC PATIENTS.

Sacituzumab Govitecan Receives Positive CHMP Opinion As 2L Treatment For Adult Patients

Oct 15 (Reuters) - Gilead Sciences Inc <GILD.O>::SACITUZUMAB GOVITECAN RECEIVES POSITIVE CHMP OPINION AS 2L TREATMENT FOR ADULT PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER.GILEAD SCIENCES - FINAL EUROPEAN COMMISSION DECISION ON MARKETING AUTHORIZATION APPLICATION FOR SACITUZUMAB GOVITECAN IS ANTICIPATED LATER IN 2021.

U.S. FDA Approves Kite’S Tecartus As The First And Only Car T For Adults With Relapsed Or Refractory B-Cell Acute Lymphoblastic Leukemia

Oct 1 (Reuters) - Gilead Sciences Inc <GILD.O>::U.S. FDA APPROVES KITE’S TECARTUS® AS THE FIRST AND ONLY CAR T FOR ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.

Kite Submits Supplemental Biologics License Application To U.S. Food And Drug Administration For Earlier Use Of Yescarta In Large B-Cell Lymphoma

Sept 30 (Reuters) - Gilead Sciences Inc <GILD.O>::KITE SUBMITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR EARLIER USE OF YESCARTA® IN LARGE B-CELL LYMPHOMA.KITE - SBLA FILING BASED ON LANDMARK ZUMA-7 STUDY, FIRST RANDOMIZED CLINICAL TRIAL TO EVALUATE CAR T AGAINST STANDARD OF CARE IN SECOND-LINE SETTING.

Nanoviricides Says Data Shows Pan-Coronavirus Nanopviricide Drug Candidate NV-Cov-2-R Minimizes Loss Of Remdesivir To Bodily Metabolism

Sept 21 (Reuters) - NanoViricides Inc <NNVC.A>::NANOVIRICIDES INC SAYS DATA SHOWS PAN-CORONAVIRUS NANOPVIRICIDE DRUG CANDIDATE NV-COV-2-R MINIMIZES LOSS OF REMDESIVIR TO BODILY METABOLISM.NANOVIRICIDES - ANTICIPATES STABILIZING EFFECT SHOULD LEAD TO HIGHLY EFFECTIVE PAN-CORONAVIRUS DRUG COULD POTENTIALLY CURE MOST CASES OF COVID-19 INFECTION.NANOVIRICIDES - NV-COV-2-R IS EXPECTED TO CONTINUE TO BE ACTIVE IN SPITE OF EVOLUTION OF NOVEL VARIANTS OF SARS-COV-2.NANOVIRICIDES - BOTH NV-COV-2 AND REMDESIVIR ARE EXPECTED TO RETAIN THEIR EFFECTIVENESS AGAINST VARIANTS OF SARS-COV-2.NANOVIRICIDES SAYS NV-COV-2 HAS SHOWN EFFECTIVENESS AGAINST MULTIPLE UNRELATED CORONAVIRUS TYPES.Further company coverage: NNVC.A. ((Reuters.Briefs@thomsonreuters.com;)).

Gilead Sciences Reports Sub-Analysis Data From Breast Cancer Phase 3 Study

Sept 16 (Reuters) - Gilead Sciences Inc <GILD.O>::TRODELVY® SIGNIFICANTLY IMPROVED QUALITY OF LIFE OVER STANDARD OF CARE IN 2L+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN PHASE 3 ASCENT STUDY.GILEAD SCIENCES - NEW SUB-ANALYSIS SHOWED SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH TRODELVY.GILEAD SCIENCES INC - SAFETY PROFILE OF TRODELVY WAS CONSISTENT WITH PRIOR REPORTS FROM ASCENT STUDY.

Galapagos H1 Net Loss Narrows To 55 Million Euros

Aug 6 (Reuters) - GALAPAGOS NV <GLPG.AS>::REPORTED ON THURSDAY H1 FINANCIAL RESULTS WITH REFOCUSED PIPELINE AND OPERATIONAL PROGRESS.H1 OPERATING LOSS OF EUR -97.6 MLN VS LOSS OF EUR -134.4 MLN YR AGO.H1 NET LOSS OF EUR -55.0 MLN VS LOSS OF EUR -165.6 MLN YR AGO.CURRENT FINANCIAL INVESTMENTS AND CASH AND CASH EQUIVALENTS OF EUR 5.01 BLN AT 30 JUNE 2021, COMPARED TO EUR 5.17 BLN ON 31 DECEMBER 2020.H1 REVENUES AND OTHER INCOME EUR 277.2 MLN VS EUR 217.2 MLN YEAR AGO.REITERATES GUIDANCE FOR 2021 OPERATIONAL CASH BURN OF EUR 580-620 MLN.IN 2021, WE EXPECT EUROPEAN REGULATORY ASSESSMENT OF FILGOTINIB FOR TREATMENT OF UC, OPINION FROM COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP), DECISION FROM EUROPEAN COMMISSION.EXPECTS ADDITIONAL REIMBURSEMENT DECISIONS FOR FILGOTINIB IN RA ACROSS NUMBER OF EUROPEAN COUNTRIES.ON TRACK TO COMPLETE TRANSITION FROM COLLABORATION PARTNER GILEAD TO GALAPAGOS OF FULL EUROPEAN COMMERCIAL OPERATIONS FOR FILGOTINIB BY YEAR-END.ANTICIPATES REPORTING ON OWN EUROPEAN SALES OF FILGOTINIB STARTING IN H2 2021.COMPLETION OF RECRUITMENT IN GLOBAL DIVERSITY PHASE 3 TRIAL WITH FILGOTINIB IN CROHN'S DISEASE BY PARTNER GILEAD EXPECTED LATER THIS YEAR.FOR SIK PORTFOLIO, WE AIM TO ADVANCE A FOLLOW-UP SIK2/3 PRECLINICAL CANDIDATE INTO THE CLINIC IN 2022.BY YEAR-END INTENDS TO FINALIZE RECRUITMENT INTO GLPG2737 PHASE 2A TRIAL IN POLYCYSTIC KIDNEY DISEASE.

Kite and Appa Bio Announce Collaboration

Aug 5 (Reuters) - Kite: :KITE AND APPIA BIO ANNOUNCE COLLABORATION TO RESEARCH AND DEVELOP ALLOGENEIC CELL THERAPIES FOR CANCER.KITE - UNDER PARTNERSHIP, CO AND APPIA BIO WILL DEVELOP CAR-ENGINEERED CAR-INKT CELLS USING APPIA BIO’S ACUA TECHNOLOGY PLATFORM.KITE - APPIA BIO TO RECEIVE UPFRONT PAYMENT, EQUITY INVESTMENT, ADDITIONAL MILESTONE PAYMENTS FOR TOTAL VALUE OF UP TO $875 MILLION WITH TIERED ROYALTIES.KITE - CO WILL BE RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING & COMMERCIALIZATION OF PRODUCT CANDIDATES IDENTIFIED THROUGH COLLABORATION.KITE - APPIA BIO RESPONSIBLE FOR PRECLINICAL, EARLY CLINICAL RESEARCH OF 2 HSC-DERIVED CAR-INKT PRODUCT CANDIDATES ENGINEERED WITH CO'S CARS.

Gilead Sciences Reports Q2 EPS Of $1.21

July 29 (Reuters) - Gilead Sciences Inc <GILD.O>::GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $1.87.Q2 EARNINGS PER SHARE $1.21.Q2 EARNINGS PER SHARE ESTIMATE $1.73 -- REFINITIV IBES DATA.QTRLY TOTAL REVENUES $6.2 BILLION VERSUS $5.14 BILLION REPORTED LAST YEAR.

Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir

July 17 (Reuters) - Gilead Sciences Inc <GILD.O>::GILEAD SCIENCES INC - NEW PHASE 3 DATA SUPPORT SUSTAINED, LONG-ACTING EFFICACY OF LENACAPAVIR, GILEAD'S INVESTIGATIONAL HIV-1 CAPSID INHIBITOR.GILEAD SCIENCES INC - LENACAPAVIR WAS GENERALLY WELL TOLERATED, WITH NO ADVERSE EVENTS.GILEAD SCIENCES INC - WEEK 26 DATA FROM CAPELLA TRIAL SHOW LENACAPAVIR LEADS TO HIGH RATES OF VIROLOGIC SUPPRESSION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up